JP2016512214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512214A5 JP2016512214A5 JP2015562176A JP2015562176A JP2016512214A5 JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5 JP 2015562176 A JP2015562176 A JP 2015562176A JP 2015562176 A JP2015562176 A JP 2015562176A JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- epitope
- amino acid
- tfpi
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789274P | 2013-03-15 | 2013-03-15 | |
| US61/789,274 | 2013-03-15 | ||
| EP13159515.9 | 2013-03-15 | ||
| EP13159515 | 2013-03-15 | ||
| PCT/EP2014/055055 WO2014140240A1 (en) | 2013-03-15 | 2014-03-14 | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512214A JP2016512214A (ja) | 2016-04-25 |
| JP2016512214A5 true JP2016512214A5 (enExample) | 2017-04-20 |
| JP6586016B2 JP6586016B2 (ja) | 2019-10-02 |
Family
ID=47877935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562176A Active JP6586016B2 (ja) | 2013-03-15 | 2014-03-14 | 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9896513B2 (enExample) |
| EP (1) | EP2970499B1 (enExample) |
| JP (1) | JP6586016B2 (enExample) |
| CN (1) | CN105209497B (enExample) |
| ES (1) | ES2926773T3 (enExample) |
| WO (1) | WO2014140240A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2379600B2 (en) | 2008-12-22 | 2020-10-14 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| PL2560993T3 (pl) * | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| CN105473619B (zh) * | 2013-07-19 | 2020-12-15 | 诺和诺德股份有限公司 | 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体 |
| ES2746805T3 (es) * | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| CN107847589B (zh) | 2015-04-01 | 2022-03-29 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体 |
| KR20230074843A (ko) | 2015-08-19 | 2023-05-31 | 화이자 인코포레이티드 | 조직 인자 경로 억제제 항체 및 그의 용도 |
| CN106554420A (zh) * | 2015-09-30 | 2017-04-05 | 上海众合医药科技股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| JP7009998B2 (ja) * | 2016-01-29 | 2022-01-26 | ソニーグループ株式会社 | 血液凝固系解析装置、血液凝固系解析システム、血液凝固系解析方法及び血液凝固系解析装置用パラメーターの決定方法 |
| BR112019008861A2 (pt) | 2016-11-01 | 2019-07-09 | Tesaro, Inc. | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| SG10201913083SA (en) | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
| JP7289913B2 (ja) | 2018-10-11 | 2023-06-12 | ファイザー・インク | Ｔｆｐｉアンタゴニストのための投薬レジメン |
| US20220008430A1 (en) * | 2018-11-07 | 2022-01-13 | Baudax Bio, Inc. | Methods of treating subjects having platelet dysfunction with iv meloxicam |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| CN112390884B (zh) * | 2019-04-09 | 2022-07-08 | 苏州大学 | Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| WO1990013540A1 (en) | 1989-04-19 | 1990-11-15 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0539975A1 (en) * | 1991-10-31 | 1993-05-05 | Teijin Limited | Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP2002505574A (ja) | 1997-04-30 | 2002-02-19 | エンゾン，インコーポレイテッド | ポリアルキレンオキシド修飾された単鎖ポリペプチド |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2305312B1 (en) | 2001-10-10 | 2015-03-04 | ratiopharm GmbH | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| US20100197573A1 (en) | 2005-06-15 | 2010-08-05 | Novo Nordisk Health Care Ag | Transglutaminase Mediated Conjugation of Growth Hormone |
| CN102300876A (zh) | 2008-12-22 | 2011-12-28 | 诺沃—诺迪斯克有限公司 | 针对组织因子途径抑制剂(tfpi)的抗体 |
| EP2379600B2 (en) * | 2008-12-22 | 2020-10-14 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| WO2012001087A1 (en) * | 2010-06-30 | 2012-01-05 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| JP6170903B2 (ja) | 2011-04-01 | 2017-07-26 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体 |
-
2014
- 2014-03-14 WO PCT/EP2014/055055 patent/WO2014140240A1/en not_active Ceased
- 2014-03-14 JP JP2015562176A patent/JP6586016B2/ja active Active
- 2014-03-14 CN CN201480027370.2A patent/CN105209497B/zh active Active
- 2014-03-14 ES ES14710541T patent/ES2926773T3/es active Active
- 2014-03-14 EP EP14710541.5A patent/EP2970499B1/en active Active
- 2014-03-14 US US14/775,108 patent/US9896513B2/en active Active
-
2018
- 2018-01-09 US US15/866,007 patent/US10717784B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512214A5 (enExample) | ||
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| AR075798A1 (es) | Proteinas de union a il-17 (interleuquina 17) | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| JP2017529097A5 (enExample) | ||
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| HRP20150439T1 (hr) | Protutijela za humani angiopoietin 2 | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
| JP2017113019A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| IL299282B1 (en) | Enhanced variable complexes of immunoglobulins | |
| JP2017518258A5 (enExample) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| JP2017508475A5 (enExample) | ||
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| JP2017529870A5 (enExample) | ||
| JP2020502198A5 (enExample) | ||
| RU2017103679A (ru) | Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение |